[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619073":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":35,"collaborators":7,"id":37,"slug":7,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":42,"eligibilityCriteria":43,"healthyVolunteers":38,"sex":44,"minAge":45,"maxAge":7,"enrollmentInfo":46,"targetDuration":7,"studyType":49,"phases":7,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},{"fullName":5,"class":6},"University Hospital, Strasbourg, France","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Philippe Barthélémy, MD","CONTACT","33 3 88 12 76 70","philippe.barthelemy@chru-strasbourg.fr",[15],{"facility":16,"status":17,"city":18,"state":7,"zip":19,"country":20,"countryCode":21,"cosmosGeoPoint":22,"geoPoint":27,"contacts":28},"Service Oncologie Médicale - CHU de Strasbourg - France","RECRUITING","Strasbourg","67091","France","FR",{"type":23,"coordinates":24},"Point",[25,26],7.74553,48.58392,{"lat":26,"lon":25},[29,30,32],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},{"name":10,"role":31,"phone":7,"phoneExt":7,"email":7},"PRINCIPAL_INVESTIGATOR",{"name":33,"role":34,"phone":7,"phoneExt":7,"email":7},"Fabien Moinard Butot, MD","SUB_INVESTIGATOR",{"type":36,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100619073",false,"NCT07339878","Criteria for Selecting First-line Metastatic Treatment for Patients With Urothelial Carcinoma","Criteria for Selecting First-line Metastatic Treatment for Patients With Urothelial Carcinoma: Observational, Multicenter, Real-world Study","FLORAL","Inclusion Criteria:\n\n* Patients over 18 years of age\n* Metastatic urothelial carcinoma\n* Treated with first-line metastatic therapy since October 2024\n\nExclusion Criteria:\n\n* Patient who expressed opposition to participating in the study","ALL","18 Years",{"count":47,"type":48},50,"ESTIMATED","OBSERVATIONAL","The standard first-line treatment for metastatic urothelial carcinoma has become the combination of Enfortumab Vedotin and Pembrolizumab following the publication of the EV-302 study results at the end of 2024. Another standard remains in 2025 for patients who are not eligible for the EV Pembrolizumab combination, namely platinum-based chemotherapy +\u002F- avelumab in cases of non-progression. The objective of the FLORAL study is to determine the characteristics of these patients and the reasons that led clinicians to prefer a first-line treatment based on platinum salts.",[52],"Metastatic Urothelial Carcinoma",[54,55,56],"Urothelial Carcinoma","Enfortumab Vedotin","Pembrolizumab","2026-01-05",{"date":59,"type":60},"2026-01-14","ACTUAL",{"date":62,"type":60},"2025-04-20",{"date":64,"type":48},"2026-04-20",{"name":5,"class":6},1]